All the news

Providing hepatitis B treatment for everyone who needs it in Malawi is an achievable public health goal, researchers from the Malawi-Liverpool-Wellcome Trust programme report, following community surveys in Blantyre, Malawi. Hepatitis B treatment ...

Around 2.5 million people with hepatitis B in sub-Saharan Africa already have cirrhosis and need immediate antiviral treatment, a systematic review of published studies reports this month in the journal Liver International. Approximately ...

Many people who take nucleoside/nucleotide antivirals for chronic hepatitis B can safely discontinue treatment, although this usually does not lead to a cure, researchers reported last week at the AASLD virtual Liver Meeting. Nucleoside/nucleotide analogues such ...

Discontinuation of long-term nucleoside/nucleotide antiviral treatment for hepatitis B can allow some people to achieve a cure, according to a pair of presentations last week at the 2020 Digital International Liver Congress. This may happen ...

Treating hepatitis B virus (HBV) with nucleoside/nucleotide antiviral drugs was associated with a lower risk of developing hepatocellular carcinoma (HCC), the most common type of liver cancer, according to studies presented last week ...

People with hepatitis B who were treated with tenofovir disoproxil fumarate (TDF; Viread) were less likely to develop hepatocellular carcinoma (HCC) than those treated with entecavir (Baraclude) in a large observational study, according ...

An experimental hepatitis B virus (HBV) core protein inhibitor led to greater reductions in HBV viral load and residual HBV genetic material when added to nucleoside/nucleotide analogues, which could lead to a functional ...

Tenofovir alafenamide (TAF; Vemlidy), the new formulation of tenofovir, continues to appear at least equally effective for treatment of hepatitis B but with a better safety profile than the older tenofovir disoproxil fumarate ...

Experimental drugs that interfere with hepatitis B virus (HBV) capsid assembly continue to show promise as a new approach to antiviral treatment, according to research presented at the AASLD Liver Meeting last ...